Yang Erin H, Muhsen Ibrahim N, Samarkandi Hadeel, El Fakih Riad, Aljurf Mahmoud, Hanbali Amr
Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
Section of Hematology and Oncology, Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
Hematol Oncol Stem Cell Ther. 2023 Jul 20;17(1):4-12. doi: 10.56875/2589-0646.1108.
Daratumumab is a first-in-class human anti-CD38 IgG1 monoclonal antibody approved for treating newly diagnosed and relapsed refractory multiple myeloma. Pre-clinical data supported daratumumab's ability to deplete autoantibodies producing plasma cells, B-cells, and NK cells. Those reports showed promising results on using daratumumab in autoimmune disorders that are refractory to multiple lines of therapies, which encouraged using daratumumab in various autoimmune conditions that are refractory to standard therapies. This review aims to summarize the literature reporting experience using anti-CD38 antibodies in hematological autoimmune diseases, focusing on the most common autoimmune hematological diseases, including autoimmune hemolytic anemia, immune thrombocytopenia, post-transplant cytopenia, and pure red blood cell aplasia.
达雷妥尤单抗是首个获批用于治疗新诊断和复发难治性多发性骨髓瘤的人抗CD38 IgG1单克隆抗体。临床前数据支持达雷妥尤单抗清除产生自身抗体的浆细胞、B细胞和自然杀伤细胞的能力。这些报告显示，在对多种治疗方案难治的自身免疫性疾病中使用达雷妥尤单抗取得了有前景的结果，这促使在对标准治疗难治的各种自身免疫性疾病中使用达雷妥尤单抗。本综述旨在总结在血液系统自身免疫性疾病中使用抗CD38抗体的文献报道经验，重点关注最常见的自身免疫性血液系统疾病，包括自身免疫性溶血性贫血、免疫性血小板减少症、移植后血细胞减少症和纯红细胞再生障碍性贫血。
